Eckert & Ziegler stock: November 12 results test Eckert & Ziegler stock

Published on 10/23/2026 at 16:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue was EUR 149.30 million. Eckert & Ziegler stock costs EUR 13.18 on October 23, 2026, down 0.90 percent versus Xetra close.

Reporting date and valuation

Eckert & Ziegler is scheduled to report third-quarter results on November 12, 2026.
First-half revenue reached EUR 149.30 million versus EUR 148.80 million a year earlier.
Eckert & Ziegler stock costs EUR 13.18 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST, 0.90 percent below the Xetra close.
The price-to-earnings ratio was 16.68 and market capitalization was EUR 825.4 million as of October 23, 2026.

CGI-Render eines modernen Unternehmensgebäudes mit Glasfassade bei Sonnenuntergang — Eckert & Ziegler DE0005659700 Medizintechnik: Architektur-Render eines modernen Firmengebäudes mit Glas-Stahl-Fassade bei Abenddämmerung in Berlin, Illustration mit AI erstellt.

Eckert & Ziegler is scheduled to publish its third-quarter report on November 12, 2026, giving investors a dated test for the company's operating progress. Trading-Treff reported the date on October 22, 2026. Eckert & Ziegler was trading at EUR 13.18 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST, down 0.90 percent versus the Xetra close of October 22, 2026 at EUR 13.30.

First-half revenue held near prior year

The latest reported interim figures show a mixed operating picture. In the first half of 2026, revenue reached EUR 149.30 million, compared with EUR 148.80 million in the prior-year period, while second-quarter revenue was EUR 76.40 million. NadirAlpha also reported second-quarter net income of EUR 12.00 million and operating income of EUR 17.40 million for the period.

Stock stays below its yearly high

The Xetra listing was last quoted at EUR 13.19 on October 23, 2026 at 4:03 p.m. CEST. Its 52-week range was EUR 11.91 to EUR 17.73 as of the same date, placing the Lang & Schwarz price 25.66 percent below the high and 10.66 percent above the low. Trading volume stood at 20,860 shares.

What will November 12 test?

The report will show whether the expected improvement in profitability is visible in reported results rather than only in forward estimates. The company operates in medical, scientific and industrial isotope technology, with its business divided into Medical and Isotope Products, according to Eckert & Ziegler. Its investor page reported EUR 312.00 million in revenue and EUR 77.70 million in adjusted EBIT for fiscal year 2025.

Valuation adds another reference point. The price-to-earnings ratio was 16.68 and market capitalization was EUR 825.4 million as of October 23, 2026. The next reporting date therefore matters for both the revenue trend and the market's assessment of earnings quality.

Price and investor perspective

The stock's EUR 13.18 quote at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST stood EUR 0.12 below the EUR 13.30 Xetra close of October 22, 2026, a decline of 0.90 percent. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.